2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines (Update From 2014 Statement): A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
View abstract on PubMed
Summary
This summary is machine-generated.This updated guidance provides a systematic approach for economic value statements in clinical guidelines, defining a new cost-effectiveness threshold and certainty framework. It also addresses health equity in cardiovascular health.
Area Of Science
- Cardiovascular Medicine
- Health Economics
- Clinical Practice Guidelines
Background
- Prior guidance on cost-effectiveness analysis (CEA) in clinical guidelines was established in 2014.
- There is a need for consistent implementation of economic value statements across guidelines.
Purpose Of The Study
- To update the methodology for incorporating CEA into clinical practice guidelines.
- To provide a framework for economic value statements and certainty levels.
- To address health equity considerations in CEA for cardiovascular health.
Main Methods
- Focused literature search of CEA methodology from 1973 to present.
- Inclusion of studies published through June 25, 2024.
- Synthesis of evidence for developing economic value statements.
Main Results
- Establishes a US cost-effectiveness threshold of $120,000 per quality-adjusted life year.
- Introduces a new framework for communicating the certainty of evidence.
- Highlights specific considerations for cardiovascular drugs and devices.
Conclusions
- The updated statement provides a systematic approach for economic value assessments in guidelines.
- Emphasizes the importance of health equity in interpreting CEA.
- Defines a reference case for future cost-effectiveness analyses.

